Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Chugai Withdraws from Medical Devices to Concentrate on Drug Business
December 10, 2001
- Kyorin to Codevelop Nail Lacquer with Maruho
December 10, 2001
- Ryukinkyo-like Discussion Forum Is Necessary: FJPWA President
December 10, 2001
- Taisho, Tanabe Cancel Their Integration
December 10, 2001
- REGULATORY NEWS IN BRIEF
December 10, 2001
- Fujisawa Hopes to Become Global Megaplayer by 2010: President Aoki
December 10, 2001
- Questions Raised Regarding NHI Prices of Interferons
December 10, 2001
- Ohki: Sales Up 2.7%, Operating Profits Up 22.0%
December 10, 2001
- Sales of 4 New Drugs Including Advaferon, Palmicort Expected to Exceed \10 Bil.
December 10, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 10, 2001
- 9 NCEs Including Glivec, Rebetol Listed
December 10, 2001
- MEDICAL DEVICE NEWS IN BRIEF
December 10, 2001
- Korosho to Regard Original Products without Generics as Long-listed
December 10, 2001
- Shimadzu: New Electronic Medical Chart System
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
December 10, 2001
- WORLD NEWS IN BRIEF
December 10, 2001
- Vital-Net: Operating Profits Drop Despite Big Increases in Sales
December 10, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -2-
December 10, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF -1-
December 10, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…